CN110575466A - Composition for increasing bone mineral density and application thereof - Google Patents
Composition for increasing bone mineral density and application thereof Download PDFInfo
- Publication number
- CN110575466A CN110575466A CN201810595497.4A CN201810595497A CN110575466A CN 110575466 A CN110575466 A CN 110575466A CN 201810595497 A CN201810595497 A CN 201810595497A CN 110575466 A CN110575466 A CN 110575466A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- content
- composition
- dietary fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000001965 increasing effect Effects 0.000 title claims abstract description 25
- 210000000988 bone and bone Anatomy 0.000 title description 37
- 229910052500 inorganic mineral Inorganic materials 0.000 title description 15
- 239000011707 mineral Substances 0.000 title description 15
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 44
- 230000037182 bone density Effects 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 26
- 241000336291 Cistanche deserticola Species 0.000 claims abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 23
- 244000197580 Poria cocos Species 0.000 claims description 13
- 235000008599 Poria cocos Nutrition 0.000 claims description 13
- 240000006079 Schisandra chinensis Species 0.000 claims description 13
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 13
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 11
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 11
- 244000131316 Panax pseudoginseng Species 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 10
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 10
- 235000006533 astragalus Nutrition 0.000 claims description 10
- 235000017803 cinnamon Nutrition 0.000 claims description 10
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 244000046146 Pueraria lobata Species 0.000 claims description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 244000061520 Angelica archangelica Species 0.000 claims description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 241000405414 Rehmannia Species 0.000 claims description 8
- 244000237330 gutta percha tree Species 0.000 claims description 8
- 241000893536 Epimedium Species 0.000 claims description 7
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 7
- 235000018905 epimedium Nutrition 0.000 claims description 7
- 240000000031 Achyranthes bidentata Species 0.000 claims description 6
- 241000045403 Astragalus propinquus Species 0.000 claims description 6
- 229920002752 Konjac Polymers 0.000 claims description 6
- 244000241838 Lycium barbarum Species 0.000 claims description 6
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000010485 konjac Nutrition 0.000 claims description 6
- 229920001202 Inulin Polymers 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 4
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 241000972672 Phellodendron Species 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000000252 konjac Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 210000004233 talus Anatomy 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 240000007371 Cuscuta campestris Species 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 241000037831 Polygonatum sibiricum Species 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 2
- 240000006766 Cornus mas Species 0.000 claims 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 48
- 241000005787 Cistanche Species 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 38
- 230000000052 comparative effect Effects 0.000 description 27
- 210000003734 kidney Anatomy 0.000 description 21
- 230000007812 deficiency Effects 0.000 description 19
- 210000000689 upper leg Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 241000209020 Cornus Species 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 241000382455 Angelica sinensis Species 0.000 description 7
- 241000723347 Cinnamomum Species 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 241000208688 Eucommia Species 0.000 description 5
- 239000009636 Huang Qi Substances 0.000 description 5
- 240000002624 Mespilus germanica Species 0.000 description 5
- 235000017784 Mespilus germanica Nutrition 0.000 description 5
- 235000000560 Mimusops elengi Nutrition 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 240000007164 Salvia officinalis Species 0.000 description 5
- 235000007837 Vangueria infausta Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 244000132619 red sage Species 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000110637 Cuscuta chinensis Species 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 206010041497 Spermatorrhoea Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000427159 Achyranthes Species 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 244000301850 Cupressus sempervirens Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000001188 Peltandra virginica Nutrition 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 235000017276 Salvia Nutrition 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 240000008866 Ziziphus nummularia Species 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 241000759833 Cornus officinalis Species 0.000 description 2
- 240000005717 Dioscorea alata Species 0.000 description 2
- 235000002723 Dioscorea alata Nutrition 0.000 description 2
- 235000007056 Dioscorea composita Nutrition 0.000 description 2
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 2
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 2
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 2
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 2
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- 241001446509 Psoralea Species 0.000 description 2
- 241000736078 Schisandra sphenanthera Species 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006278 hypochromic anemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000017524 noni Nutrition 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- BWSIKGOGLDNQBZ-LURJTMIESA-N (2s)-2-(methoxymethyl)pyrrolidin-1-amine Chemical compound COC[C@@H]1CCCN1N BWSIKGOGLDNQBZ-LURJTMIESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000222382 Agaricomycotina Species 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 244000024251 Aralia cordata Species 0.000 description 1
- 235000014722 Aralia cordata Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241001264766 Callistemon Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241000252804 Cinnamomum insularimontanum Species 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 241000207901 Cuscuta Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001116742 Drynaria Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000218218 Ficus <angiosperm> Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001596950 Larimichthys crocea Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000157491 Morinda Species 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 235000008898 Morinda citrifolia Nutrition 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 241000431987 Neocheiropteris fortunei Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241000196124 Polypodiaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000226566 Psoralea corylifolia Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- -1 monoterpene phenols Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a composition for increasing bone density, comprising: 2-3 parts of cistanche deserticola; 25-35 parts of dietary fiber. Compared with the prior art, the raw materials adopted by the composition provided by the invention are all natural medicines and new resource foods, are safe to human bodies and have no side effect, and the composition is prepared according to a reasonable proportion, so that the synergistic effect of the cistanche and the dietary fibers is fully exerted, and a better effect of increasing the bone density is achieved.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composition for increasing bone mineral density and application thereof.
Background
Osteoporosis (OP) is a systemic skeletal disease mainly characterized by a decrease in bone mass, a change in microstructure of bone tissue, an increase in bone fragility and an increase in risk of fracture, and is frequently found in postmenopausal women, the elderly, and patients with various chronic diseases. The incidence rate of osteoporosis is very high, and according to the national large-scale epidemiological investigation and research, about 1.6 hundred million people in China have osteoporosis, which accounts for nearly 12.4 percent of the total population in China. Research by the international osteoporosis foundation predicts that the number of people with osteoporosis will reach 2.866 billion by 2020. Osteoporosis will become a more serious public health problem as life expectancy increases and population architecture changes.
Osteoporosis is thought to be associated with or result from factors such as sex hormone deficiency, calcium loss or insufficient calcium intake, lack of mobility, etc., leading to loss of bone mass, destruction of trabecular bone microstructure, and decreased bone mechanical properties. At present, no specific medicine exists for treating osteoporosis, the effects of increasing bone mineral density and preventing and treating osteoporosis are achieved mainly by absorbing functional components related to bone mineral density and direct calcium-containing components, but the products of the type only stay at the level of improving symptoms and delaying disease development from the aspect of treatment effect, the effects of reversing disease conditions and even curing cannot be achieved, and some clinically used chemical synthetic medicines have obvious side effects and are easy to cause complications after being taken for a long time. Therefore, the development of a product which is safe and can effectively increase the bone density so as to reverse the consolidation and loosening state of illness has very important significance.
Disclosure of Invention
In view of the above, the present invention provides a composition for increasing bone density and its application.
the present invention provides a composition for increasing bone density, comprising:
2-3 parts of cistanche deserticola;
25-35 parts of dietary fiber.
Preferably, the dietary fiber is selected from one or more of inulin, konjac, soybean dietary fiber, soybean polysaccharide, corn starch, resistant dextrin, cyclodextrin, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, sodium carboxymethyl cellulose and microcrystalline cellulose.
preferably, the content of the cistanche is 2.5-3 parts by weight; the content of the dietary fiber is 30 parts by weight.
Preferably, one or more of fructus Psoraleae, rhizoma Drynariae and herba Epimedii are also included; the content of the fructus psoraleae is 2-3 parts by weight; the content of the rhizoma drynariae is 1-1.5 parts by weight; the content of the epimedium is 2-3 parts by weight.
Preferably, one or more of cortex Eucommiae, radix Puerariae, rhizoma Polygonati, rhizoma Dioscoreae, fructus Lycii, radix Notoginseng, Poria, radix astragali and radix Achyranthis bidentatae are also included; the content of the eucommia ulmoides is 2-3 parts by weight; the content of the kudzu root is 3.5-5 parts by weight; the content of the sealwort is 3-4.5 parts by weight; the content of the Chinese yam is 5-7.5 parts by weight; the content of the wolfberry fruit is 2-3 parts by weight; the content of the pseudo-ginseng is 1-1.5 parts by weight; the content of the poria cocos is 3.5-5 parts by weight; the content of the astragalus is 3-4.5 parts by weight; the content of the achyranthes bidentata is 2-2.5 parts by weight.
preferably, one or more of fructus Schisandrae chinensis, semen Cuscutae, radix rehmanniae Preparata, Corni fructus, cortex Phellodendri, Saviae Miltiorrhizae radix, radix Angelicae sinensis, radix Morindae officinalis and cortex Cinnamomi are also included; the content of the schisandra chinensis is 0.7-1 part by weight; the content of the semen cuscutae is 2-3 parts by weight; the content of the prepared rhizome of rehmannia is 3-4.5 parts by weight; the content of the dogwood is 2-3 parts by weight; the content of the phellodendron is 1-1.5 parts by weight; the content of the salvia miltiorrhiza is 3.5-5 parts by weight; the content of the angelica is 2-3 parts by weight; the content of the morinda officinalis is 1-1.5 parts by weight; the content of the cinnamon is 0.4-0.5 part by weight.
Preferably, the method comprises the following steps:
Preferably, the method comprises the following steps:
The invention also provides application of the composition in preparing health products for improving and/or preventing osteoporosis.
The invention also provides application of the composition in preparing a medicament for treating and/or preventing osteoporosis.
The present invention provides a composition for increasing bone density, comprising: 2-3 parts of cistanche deserticola; 25-35 parts of dietary fiber. Compared with the prior art, the raw materials adopted by the composition provided by the invention are all natural medicines and new resource foods, are safe to human bodies and have no side effect, and the composition is prepared according to a reasonable proportion, so that the synergistic effect of the cistanche and the dietary fibers is fully exerted, and a better effect of increasing the bone density is achieved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
the present invention provides a composition for increasing bone density, comprising:
2-3 parts of cistanche deserticola;
25-35 parts of dietary fiber.
In the present invention, the sources of all raw materials are not particularly limited, and the raw materials may be commercially available or self-made.
According to the present invention, the content of cistanche is preferably 2.5 to 3 parts by weight, and more preferably 3 parts by weight. Cistanchis herba is dry succulent stem with scale leaf of Cistanchis herba Deserticola Y.C.Ma or Cistanchis herba Tubuliosa (Schenk) light of Orobanchaceae, also named as herba Gei, herba Cistanchis, and herba Cistanchis. The cistanche deserticola can directly or indirectly influence the activities of osteoblasts and osteoclasts by improving the level of sex hormone, regulating the balance of calcium and phosphorus metabolism, resisting oxidation, influencing cell factors, supplementing mineral elements and the like, thereby playing a role in preventing and treating osteoporosis.
The content of the dietary fiber is preferably 30-35 parts by weight, and more preferably 30 parts by weight; the dietary fiber is not particularly limited as long as it is known to those skilled in the art, and in the present invention, one or more of inulin, konjac, soybean dietary fiber, soybean polysaccharide, corn starch, resistant dextrin, cyclodextrin, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, sodium carboxymethyl cellulose, and microcrystalline cellulose are preferable; wherein, the konjak is preferably konjak flour; the soybean dietary fiber is preferably soybean dietary fiber powder. The dietary fiber is carbohydrate which can not be digested by human bodies, but the dietary fiber can generate short-chain fatty acid through the glycolysis of intestinal microorganisms, can influence the metabolism of osteoclasts, obviously reduces bone absorption and increases bone density; and the short-chain fatty acid can increase the immunity of a human body, supplement the short-chain fatty acid or perform high dietary fiber diet, can prevent calcium loss caused by osteoporosis and arthritis after menopause, and can relieve inflammation to a certain extent.
The invention creatively discovers that the effect of increasing the bone density of cistanche and dietary fiber can be better exerted by combining the cistanche and the dietary fiber, and the effect of the obtained composition is far higher than that of any one of the raw materials which are singly used.
According to the invention, in order to better increase the bone density, the composition preferably further comprises kidney-tonifying yang-invigorating medicines, but when different kidney-tonifying yang-invigorating medicines are added, different medicines are added simultaneously to increase the effect from multiple aspects, so that the composition provided by the invention preferably further comprises one or more of fructus psoraleae, rhizoma drynariae and herba epimedii besides the cistanche and the dietary fiber.
The content of the fructus psoraleae is preferably 2-3 parts by weight, more preferably 2.5-3 parts by weight, and even more preferably 3 parts by weight. The fructus Psoraleae is dry mature fruit of Psoralea corylifolia L (Psoralea corilifolia L.) belonging to Leguminosae, has effects of warming kidney, tonifying yang, promoting inspiration, relieving asthma, warming spleen and relieving diarrhea, and can be used as raw material for health food. Fructus Psoraleae contains various active ingredients, mainly including coumarins, flavonoids and monoterpene phenols, wherein the coumarins have good anti-osteoporosis activity.
The content of the rhizoma drynariae is preferably 1 to 1.5 parts by weight, and more preferably 1.5 parts by weight. The rhizoma Drynariae is dried rhizome of Drynariae rhizoma (Drynaria fortunei (Kunze) J.Sm.) of Polypodiaceae, and has effects of invigorating kidney and strengthening bone. Modern researches show that the total flavonoids of the rhizoma drynariae can improve the activity of osteoblasts, can obviously improve the bone density of ovariectomized rats and has obvious prevention and treatment effects on osteoporosis caused by ovariectomy.
The content of the epimedium herb is preferably 2-3 parts by weight, more preferably 2.5-3 parts by weight, and even more preferably 3 parts by weight. Herba Epimedii is whole herb of perennial herb herba Epimedii or Epimedium sagittatum of berberidaceae, is warm in nature, pungent and sweet in flavor, enters liver and kidney channels, and has effects of invigorating kidney, tonifying yang, dispelling pathogenic wind and removing dampness. The study proves that the epimedium can obviously relieve the symptoms of the bone pain, improve biochemical indexes of the bone metabolism and increase the cancellous bone density, the effective rate reaches 93.3 percent, and the effective rate has no significant difference compared with the effective rate of the sex hormone replacement therapy.
or the composition provided by the invention preferably comprises one or more of eucommia bark, kudzu root, rhizoma polygonati, Chinese yam, medlar, pseudo-ginseng, tuckahoe, astragalus and achyranthes besides the cistanche and the dietary fiber.
The content of the eucommia ulmoides is preferably 2-3 parts by weight, more preferably 2.5-3 parts by weight, and even more preferably 3 parts by weight. Eucommia bark, which is the dry bark of eucommia ulmoides of the family eucommia, is a rare nourishing medicinal material in China, has sweet taste and warm property, can tonify liver and kidney, strengthen tendons and bones, and prevent miscarriage, and is used for treating deficiency of liver and kidney, soreness and pain of waist and knees, flaccidity of lower limbs, impotence and frequent micturition; liver and kidney deficiency, pregnancy bleeding, threatened abortion, or habitual abortion; hypertension.
The content of the kudzu root is preferably 3.5 to 5 parts by weight, more preferably 4 to 5 parts by weight, still more preferably 4.5 to 5 parts by weight, and most preferably 5 parts by weight. Pueraria lobata (Willd.) Ohwi is dry root of Pueraria lobata Ohwi of Leguminosae, and is called as Pueraria lobata Ohwi. Collected in autumn and winter, cut into thick slices or small pieces when fresh, dried, sweet, pungent and cool, and has the effects of relieving muscles and fever, promoting eruption, promoting the production of body fluid to quench thirst, and invigorating yang to arrest diarrhea, and is commonly used for exterior syndrome fever, neck and back pain, measles without adequate eruption, fever thirst, yin deficiency to quench thirst, heat diarrhea and dysentery, and spleen deficiency to purge.
The content of the sealwort is preferably 3 to 4.5 parts by weight, more preferably 3.5 to 4.5 parts by weight, still more preferably 4 to 4.5 parts by weight, and most preferably 4.5 parts by weight. Polygonatum sibiricum, rhizoma polygonati, yellow croaker, rhizoma callistemon, rhizome of red sage, tiger ginger and rhizome of red sage are plants in the genus of Polygonatum, the rhizome of the plants is horizontally moved, the plants are cylindrical, the nodes are expanded, the plants are impeller-grown, and the plants have no handle, are medicinal plants and have the effects of tonifying spleen, moistening lung and promoting the secretion of saliva or body fluid.
The content of the yam is preferably 5-7.5 parts by weight, more preferably 6-7.5 parts by weight, and still more preferably 7.5 parts by weight. The yam is a clinically common medicine, is sweet and neutral, has the effects of invigorating qi and nourishing yin, tonifying spleen and lung, reinforcing kidney and replenishing marrow, controlling nocturnal emission and stopping leukorrhagia, strengthening bones and muscles and stopping lumbago, and is mainly used for treating spleen deficiency and poor appetite, fatigue and weakness, loose stool and diarrhea, lung deficiency cough, kidney deficiency and spermatorrhea, morbid leucorrhea, frequent micturition, internal heat and thirst and the like.
The content of the wolfberry fruit is preferably 2 to 3 parts by weight, more preferably 2.5 to 3 parts by weight, and still more preferably 3 parts by weight. Fructus Lycii is mature fruit of Lycium barbarum L of Solanaceae, and is rich in Lycium barbarum polysaccharides, fat, protein, free amino acids, taurine, betaine, vitamin B1, vitamin B2, vitamin E, and vitamin C, especially carotenoid. In addition, it also contains abundant mineral elements, such as potassium, sodium, calcium, magnesium, iron, copper, manganese, zinc, selenium, etc. Has obvious effects on yin deficiency of liver and kidney, blood deficiency and chlorosis, consumptive disease and essence deficiency, soreness and weakness of waist and knees, dizziness and other diseases. It is sweet in taste and neutral in nature, and has the effect of tonifying liver and kidney, so in Ben Cao gang mu, it says "Long-time taking strengthens the muscles and bones, reducing weight, not aging, and resisting cold and summer heat". Modern pharmacological studies prove that the medlar can regulate the immunologic function of organisms, can effectively inhibit tumor growth and cell mutation, has the effects of delaying senility, resisting fatty liver, regulating blood fat and blood sugar, promoting hematopoietic function and the like, and is applied to clinic.
The content of the pseudo-ginseng is preferably 1 to 1.5 parts by weight, and more preferably 1.5 parts by weight. Pseudo-ginseng is also named pseudo-ginseng, is one of traditional and precious Chinese medicinal materials in China, is one of forty large medicinal material varieties, has an application history for over 400 years from now to now, is famous permanently at home and abroad, has the name of a hemostatic psychotropic drug since ancient times, and is named as 'Jinbuhui' by a famous pharmacologist Li Shizhen. Notoginseng radix has effects of removing blood stasis, stopping bleeding, subsiding swelling and relieving pain, and can be used for treating hemoptysis, hematemesis, epistaxis, hematochezia, metrorrhagia and metrostaxis, traumatic hemorrhage, thoracico-abdominal pain, and traumatic swelling and pain. Studies have shown that Panax Notoginseng Saponins (PNS) can improve the decrease of bone mass and bone strength caused by long-term application of hormones by inhibiting the apoptosis of osteoblasts.
The content of the poria cocos is preferably 3.5-5 parts by weight, more preferably 4-5 parts by weight, still more preferably 4.5-5 parts by weight, and most preferably 5 parts by weight. Poria, also known as Yuling, Fu Ling, Wanling Gui, Fu Tu, is the dry sclerotium of Poria cocos (a fungus) belonging to family Hymenomycetes. Poria has sweet, bland and mild flavor, enters heart, lung and spleen channels, and has the effects of excreting dampness, promoting diuresis, strengthening spleen and stomach, calming heart and tranquilizing mind.
The content of the astragalus is preferably 3 to 4.5 parts by weight, more preferably 4 to 4.5 parts by weight, and still more preferably 4.5 parts by weight. Astragalus membranaceus, also called Astragalus membranaceus or Astragalus membranaceus, has the effects of qi-strengthening, exterior-surface retention, sweating arrest, pus-holding, granulation-promoting, diuresis-inducing and edema-alleviating, and is used for treating qi deficiency and weakness, collapse of middle-qi, chronic diarrhea and rectocele, hematochezia and metrorrhagia, exterior deficiency and spontaneous perspiration, carbuncle, cellulitis and ulceration, chronic ulceration and non-healing, blood deficiency and sallow complexion, internal heat and thirst-quenching, chronic nephritis, proteinuria, diabetes and the like. Also has antitumor and osteoporosis resisting effects.
The content of the achyranthes bidentata is preferably 2-2.5 parts by weight, and more preferably 2.5 parts by weight. Achyranthes bidentata (a scientific name: Achyranthus bidentis Blume) is a perennial herb of the genus Achyranthus of the family Amaranthaceae, the root of which contains saponin, ecdysterone and Achyranthes bidentata sterone, and has the effects of removing blood stasis, dredging channels, nourishing liver and kidney, strengthening bones and muscles, inducing diuresis, treating stranguria and the like when used as a medicine.
Or the composition provided by the invention preferably comprises one or more of schisandra chinensis, semen cuscutae, prepared rhizome of rehmannia, dogwood, golden cypress, salvia miltiorrhiza, angelica sinensis, morinda officinalis and cinnamon besides the cistanche and the dietary fibers.
The content of the schisandra chinensis is preferably 0.7-1 part by weight, and more preferably 1 part by weight. Schisandra chinensis (Turcz.) Baill is dried mature fruit of Schisandra chinensis (Schisandra chinensis, Magnoliaceae) or Schisandra sphenanthera (Schisandra sphenanthera). The schisandra chinensis is sweet and sour in taste and warm in nature, can tonify qi, promote the production of body fluid, tonify kidney, nourish heart, astringe and arrest, and is used for qi deficiency, body fluid injury, tiredness, hyperhidrosis, shortness of breath and palpitation; cough and dyspnea caused by deficiency of lung qi or deficiency of both lung and kidney, or chronic cough and dyspnea with lung qi consumption; heart yin deficiency, palpitation, insomnia and amnesia; insecurity of kidney qi, seminal emission, frequent urination, or deficiency of both the spleen and kidney, persistent diarrhea. It is also used for anicteric hepatitis and persistent chronic hepatitis.
The content of the dodder is preferably 2-3 parts by weight, more preferably 2.5-3 parts by weight, and even more preferably 3 parts by weight. Cuscuta chinensis (scientific name: Cuscuta chinensis), also known as semen Cuscutae, Myrtle, Ficus efflorens and semen Cuscutae, is a seed of the genus Cuscuta of the family Convolvulaceae. Dodder is a good medicine for tonifying kidney, liver and spleen, and is mainly clinically applied to kidney yin-yang deficiency syndromes such as lumbago due to kidney deficiency, impotence, spermatorrhea, frequent micturition, infertility due to cold womb, dark eyes and loose stool.
the content of the prepared rhizome of rehmannia is preferably 3 to 4.5 parts by weight, more preferably 4 to 4.5 parts by weight, and still more preferably 4.5 parts by weight. The radix rehmanniae Preparata is prepared from radix rehmanniae (radix rehmanniae Preparata or radix rehmanniae Preparata) of Scrophulariaceae family by processing. Radix rehmanniae Preparata is a good Chinese medicinal material, has effects of replenishing blood and nourishing yin, and can be used for treating blood deficiency and chlorosis, giddiness, cardiopalmus and insomnia, menoxenia, metrorrhagia, etc., and can also be used for treating hectic fever and hectic fever due to deficiency of kidney yin, night sweat, spermatorrhea, diabetes, etc.
The content of the dogwood is preferably 2 to 3 parts by weight, more preferably 2.5 to 3 parts by weight, and even more preferably 3 parts by weight. Cornus officinalis, also called cornus officinalis meat, medicinal jujube, jujube peel, jujube pulp and the like, is a common and rare Chinese medicinal material in China and has a long history of application. It is favored by the medical generations with special efficacies of mild tonifying power, yang strengthening without promoting fire, yin nourishing without greasy diaphragm, convergence without retaining pathogenic factors, etc. According to chemical analysis, the dogwood contains dogwood glycoside with strong physiological activity, tartaric acid, gallic acid, malic acid, resin, tannin, multiple vitamins and other effective components, has pharmacological effects of enhancing immunity, resisting inflammation, resisting bacteria and the like, and is a common medicine in the clinical traditional Chinese medicine. Research shows that the dogwood water extract can obviously improve the osteoporosis symptom of an osteoporosis model mouse (SAMP/6).
the content of the phellodendron amurense is preferably 1 to 1.5 parts by weight, and more preferably 1.5 parts by weight. Cortex Phellodendri is bark of phellodendron amurense belonging to Rutaceae, such as cortex Phellodendri, and cortex Phellodendri. Cortex Phellodendri has effects of clearing heat and detoxicating, and eliminating dampness, and can be used for treating damp-heat dysentery, diarrhea, jaundice, nocturnal emission, stranguria with turbid urine, leukorrhagia, etc.
The content of the salvia miltiorrhiza is preferably 3.5 to 5 parts by weight, more preferably 4 to 5 parts by weight, still more preferably 4.5 to 5 parts by weight, and most preferably 5 parts by weight. Salvia miltiorrhiza (scientific name: Salvia milirhizohiza Bunge) is a perennial upright herb of the genus Salvia of the family Labiatae, which is dicotyledonous, thick in root, red in outer vermilion, white in inner part, fleshy, often has odd feathered, multiple leaves, terminal or axillary inflorescence; the bract is in the shape of needles, the calyx is in a bell shape, the bract is purple, the corolla is purple blue, the style of flower column extends far outwards, the small nuts are black and oval, the flowers bloom in 4-8 months, the fruits appear after the flowers appear, the medicine is taken as the root, contains tanshinone, is a strong menstrual flow stimulating agent, has the effects of removing blood stasis, promoting tissue regeneration, promoting blood circulation, regulating menstruation and the like, is a key gynecological medicine, is mainly used for treating metrorrhagia, irregular menstruation, blood stasis, abdominal pain, menstrual pain, amenorrhea and temple pain, and has a good effect of treating coronary heart disease. In addition, the medicine also can be used for treating insomnia caused by neurasthenia, arthralgia, anemia, mastitis, lymphadenitis, arthritis, sore and furuncle pain and swelling, erysipelas, acute and chronic hepatitis, kidney menyan nephritis, traumatic injury, liver and spleen swelling caused by late schistosomiasis, and epilepsy 30286. It can be used for external application to wash paint sore.
The content of the angelica is preferably 2 to 3 parts by weight, more preferably 2.5 to 3 parts by weight, and even more preferably 3 parts by weight. Angelica (with the scientific name: Angelica sinensis) is named as Angelica sinensis, Qina, Xiangelicas, Minangelicas, Angelica sinensis cauda, Angelica sinensis Dahurica and Aralia cordata, and is perennial herbaceous, 0.4-1 meter high, 6-7 months in flowering phase and 7-9 months in fruit phase. In 1957, Europe angelica is introduced from Europe, the southeast part of Gansu is the main product, the Min county has more yield and good quality, and Yunnan, Sichuan, Shaanxi, Hubei and other provinces are cultivated. Some provinces in China also introduce and cultivate. The root of the Chinese medicinal composition can be used as a medicament, is one of the most common Chinese medicaments, and has the effects of tonifying blood and regulating blood, regulating menstruation and relieving pain, moistening dryness and lubricating intestines, resisting cancer, resisting aging and preventing aging and immunizing.
The content of morinda officinalis is preferably 1-1.5 parts by weight, and more preferably 1.5 parts by weight. Morinda officinalis (scientific name: Morinda officinalis How) is dicotyledonous plant Rubiaceae, 3-13 cm long, 1.5-5 cm wide, tapered at the front end, blunt or round at the base. The dry root of Morinda citrifolia is flat cylindrical and slightly curved. It can be used for treating sexual impotence, spermatorrhea, infertility due to cold womb, menoxenia, psychroalgia of lower abdomen, rheumatalgia, and flaccidity of tendons and bones.
The content of cinnamon is preferably 0.4-0.5 parts by weight, and more preferably 0.5 parts by weight. Cinnamon (the scientific name of Latin: Cinnamomum cassia Presl), also called Yugui, Japanese cinnamon, caju, Dagui, Pimenta, Ping' an tree, Chinese cinnamon, is the dry bark of cinnamon of Lauraceae, and has the main treatment functions of: tonify primordial yang, warm spleen and stomach, remove cold accumulation, and promote blood circulation. It is indicated for decline of vital gate fire, cold limbs and pulse, yang exhaustion and collapse, abdominal pain and diarrhea, cold hernia and dolphin, cold pain in waist and knee, amenorrhea, deep rooted carbuncle, abscess, and floating yang, upper heat and lower cold.
Or, according to the present invention, the composition for increasing bone density preferably further comprises one or more of fructus psoraleae, rhizoma drynariae, herba epimedii, eucommia ulmoides, radix puerariae, rhizoma polygonati, Chinese yam, fructus lycii, pseudo-ginseng, poria cocos, radix astragali, radix achyranthis bidentatae, fructus schizandrae, semen cuscutae, radix rehmanniae preparata, fructus corni, cortex phellodendri, radix salviae miltiorrhizae, radix angelicae sinensis, radix morindae officinalis and cortex cinnamo.
The invention discovers that the effect of the composition can be further improved by combining the cistanche, the dietary fiber and any one or more of fructus psoraleae, rhizoma drynariae, epimedium herb, eucommia bark, kudzu root, rhizoma polygonati, Chinese yam, medlar, pseudo-ginseng, tuckahoe, astragalus root, achyranthes root, schisandra fruit, dodder, prepared rhizome of rehmannia, dogwood, phellodendron, salvia miltiorrhiza, angelica, morinda officinalis and cinnamon.
more preferably, the present invention provides a composition comprising: herba cistanches, dietary fiber, fructus psoraleae, rhizoma drynariae, herba epimedii, cortex eucommiae, radix puerariae, rhizoma polygonati, Chinese yam, fructus lycii, pseudo-ginseng, poria cocos, radix astragali and radix achyranthis bidentatae; the herba cistanches, the dietary fibers, the fructus psoraleae, the rhizoma drynariae, the herba epimedii, the eucommia ulmoides, the radix puerariae, the rhizoma polygonati, the Chinese yam, the fructus lycii, the radix notoginseng, the poria cocos, the radix astragali and the radix achyranthis bidentatae are the same as those described above, and are not described again.
Still more preferably, the present invention provides a composition comprising:
Most preferably, the present invention provides a composition comprising:
The raw materials adopted by the composition provided by the invention are all natural medicines and new resource foods, are safe to human bodies and have no side effect, and the composition is prepared according to a reasonable proportion, so that the synergistic effect of the cistanche and the dietary fibers is fully exerted, and a better effect of increasing the bone density is achieved.
The invention also provides a preparation method of the composition for increasing bone density, which comprises the following steps:
Mixing 2-3 parts by weight of cistanche and 25-35 parts by weight of dietary fiber to obtain the composition for increasing bone density.
According to the invention, one or more of fructus psoraleae, rhizoma drynariae, herba epimedii, eucommia ulmoides, radix puerariae, rhizoma polygonati, Chinese yam, medlar, pseudo-ginseng, poria cocos, astragalus mongholicus, radix achyranthis bidentatae, schisandra chinensis, semen cuscutae, radix rehmanniae preparata, dogwood, golden cypress, radix salviae miltiorrhizae, angelica sinensis, morinda officinalis and cinnamon are preferably added.
The cistanche, the dietary fiber, the psoralea fruit, the drynaria rhizome, the epimedium herb, the eucommia bark, the root of kudzu vine, the rhizoma polygonati, the Chinese yam, the fruit of Chinese wolfberry, the pseudo-ginseng, the poria cocos, the astragalus mongholicus, the root of bidentate achyranthes, the schisandra chinensis, the seed of Chinese dodder, the prepared rhizome of rehmannia, the dogwood, the golden cypress, the root of red-rooted salvia, the angelica sinensis, the morinda.
in the invention, the various traditional Chinese medicine raw materials can be directly ground and mixed with the dietary fiber, or can be extracted, filtered, concentrated and dried to obtain an extract and mixed with the dietary fiber. Wherein, the extraction method is a method known by persons skilled in the art, and is not limited in particular, and the traditional Chinese medicine raw materials provided by the invention can be extracted by water, such as epimedium, rhizoma polygonati, Chinese yam, medlar, tuckahoe, schisandra chinensis, prepared rhizome of rehmannia, dogwood, angelica and morinda officinalis; alcohol-extracted cortex Eucommiae, radix Notoginseng, radix Achyranthis bidentatae, semen Cuscutae, cortex Phellodendri, and cortex Cinnamomi; the Chinese medicinal materials include herba cistanches, fructus Psoraleae, rhizoma Drynariae, radix Puerariae, radix astragali and radix Salviae Miltiorrhizae.
The invention also provides an application of the composition in preparing a product for enhancing bone density. The product is well known to those skilled in the art, and is not particularly limited, and preferably further comprises conventional adjuvants such as disintegrating agent, lubricant, binder, etc.; the dosage form of the product is oral preparation known to those skilled in the art, and is not particularly limited, and in the present invention, one or more of powder, tablet, oral liquid, granule, dripping pill and capsule are preferred.
the invention also provides an application of the composition in preparing health products for improving and/or preventing osteoporosis. The health care product preferably also comprises auxiliary materials acceptable for the health care product, such as a disintegrating agent, a lubricant, an adhesive and the like; the dosage form of the health product is an oral preparation well known to those skilled in the art, and is not particularly limited, and in the invention, one or more of powder, tablets, oral liquid, granules, dripping pills and capsules are preferred.
The invention also provides application of the composition in preparing a medicament for treating and/or preventing osteoporosis. The medicine preferably also comprises pharmaceutically acceptable auxiliary materials, such as a disintegrating agent, a lubricant, an adhesive and the like; the dosage form of the medicament is oral preparation known to those skilled in the art, and is not particularly limited, and in the present invention, one or more of powder, tablet, oral liquid, granule, dripping pill and capsule are preferred.
In order to further illustrate the present invention, the following will describe a composition for increasing bone density and its application in detail with reference to the examples.
the reagents used in the following examples are all commercially available.
Examples
A composition for increasing bone density comprises the components and parts by weight shown in Table 1.
TABLE 1 Components and amounts of the compositions of the examples
Wherein the dietary fiber in examples 3, 6 and 8 is inulin, the dietary fiber in example 1 is soybean dietary fiber powder, the dietary fiber in example 2 is konjac flour, the dietary fiber in example 4 is resistant starch, the dietary fiber in example 5 is resistant dextrin, and the dietary fiber in example 7 is sodium carboxymethyl cellulose.
Comparative example
The composition comprises the components and parts by weight shown in table 2.
TABLE 2 Components and amounts of comparative example compositions
Wherein the dietary fiber in comparative examples 2-4 and comparative example 10 is inulin.
The preparation method comprises the following steps: extracting the Chinese medicinal materials except the dietary fibers according to the components and contents shown in the tables 1 and 2, filtering, concentrating, drying to obtain extracts, crushing the extracts, sieving, and mixing with the corresponding dietary fibers to obtain the composition. In actual use, the preparation is prepared into a required preparation form by a conventional method. The active ingredients prepared by the invention can be prepared into various oral preparations, such as tablets, capsules, granules, dripping pills, soft capsules, oral liquid and the like, by adding conventional auxiliary materials, such as a disintegrating agent, a lubricant, an adhesive and the like, by adopting a conventional and known corresponding preparation method.
to further prove the advantages of the present invention, the present invention performed a verification of the effect of increasing bone density on the compositions of the above examples and comparative examples.
1. Establishment and grouping of animal models with function of removing ovarian bone density and reducing animal density
Experimental animals adult and female SD rats of 3 months of age, SPF grade, and 200 + -20 g of body weight are selected. SD rats are randomly divided into a pseudo-operation group, a model control group, a positive control group, examples 1-8 groups and comparative examples 1-10 groups, wherein the examples 1-8 groups and the comparative examples 1-10 groups are further divided into a high-dose group, a medium-dose group and a low-dose group. Rats in a model control group, a positive control group, examples 1-8 groups and comparative examples 1-10 groups are anesthetized by intraperitoneal injection of 30mg/kg sodium pentobarbital solution, hairs are removed at a position 3-4 cm away from a vaginal opening by using a shaver after abdominal fixation, and after double disinfection by alcohol and iodine, the abdominal opening is torn to two sides to find an ovarian position. The ovariofallopian tube was tied with surgical thread, both ovaries were cut off, and finally the wound was sutured and penicillin was scattered. Sham rats underwent similar surgery without removal of bilateral ovaries, with a small amount of fat trimmed from around the ovaries. After the surgery was completed, the rats were placed near the warm stove for recovery and a continuous 3d intramuscular injection of penicillin was used to prevent infection (20 ten thousand units per day). On day 5 after surgery, gavage administration was started after the animal status recovered to normal.
2. Method of administration and observation of results
By adopting a gastric perfusion administration method, rats in groups 1-8 and groups 1-9 of examples are administered with the medicaments (namely the compositions shown in tables 1 and 2) in the groups 1-8 and 1-9 of comparative examples, wherein the administration dose of the high-dose group is 800 mg/kg/time, the administration dose of the medium-dose group is 400 mg/kg/time, the administration dose of the low-dose group is 200 mg/kg/time, and the administration volume is 10ml/kg by using deionized water; the positive control group is administered with estradiol with a dosage of 1.0mg/kg and prepared with deionized water, and the administration volume is 10 ml/kg; the sham-operated rats and model control rats were given deionized water (10 ml/kg). The administration is continued for 12 weeks, 1 time per day. The influence of the compositions in each group on the bone density of rats is measured, and the measurement indexes and the measurement method are as follows:
1) weight: measurements were taken once a week.
2) Bone density determination: removing muscle and soft tissue from left femur of rat, soaking in normal saline, placing in sterile gauze, placing gauze-wrapped femur in EP tube, scanning with dual-energy X-ray bone densitometer, and measuring BMD (g/cm) value of whole femur2)。
3) Measuring the dry weight of the thighbone: the test end was subjected to an atomic absorption or chemical digestion assay on a left femur at constant weight.
4) Morphological study of femoral bone tissue: the right femur was removed, muscle and soft tissue removed, the proximal trochanter of the femur was cut perpendicularly approximately 1cm along the femur with a cutter, the rat right leg femur was fixed in a cylindrical sample bottle, and each sample was scanned and the distal femur was reconstructed and analyzed by extending longitudinally 2.0mm proximally from the apex of the distal primary cancellous bone. And (3) determining the content of bone minerals, the density of tissue minerals, the number of trabeculae and the separation degree of the trabeculae.
Data are presented as mean ± standard deviation, with significant differences indicated by P < 0.05.
3. Results of the experiment
1) Effect of different compositions on rat body weight
After the rats were administered with gastric lavage for 12 weeks, the body weight difference between the rats before and after administration was observed, and the influence of the high, medium and low dose groups of each example on the body weight of the ovariectomized rats was examined, and the results are shown in Table 3.
Table 3 rat body weight test results
Note:#P <0.05, vs. sham;*Represents P <0.05, vs. OVX; a. b, c, d, e, f, g and h represent multiple comparisons among groups of the medium dose groups of the examples and the comparative examples, and different letters are marked to represent statistical significance, and P is less than 0.05.
all rats were randomly assigned to body weight before the experiment, and there was no significant difference in body weight among the rats in each group. After the rats were gavaged for 12 weeks, the weight of the rats in the sham operated group was observed to increase with the feeding time, following the natural growth of the animals. The rats in the model control group show a rapid growth trend, the weight is increased by 84.69 +/-5.68 and is obviously higher than that in the false operation group (p <0.05), and the phenomenon just accords with the typical symptoms of human menopause, which indicates that the model is successfully established. The reason for the weight gain is due to loss of estrogen and transformation of bone marrow stromal cells into adipocytes after ovariectomy. Compared with a model control group, the compositions of the examples and some comparative examples can inhibit excessive weight increase, and multiple comparisons among groups of medium-dose groups of the examples and the comparative examples show that the effects of the examples are remarkably superior to those of the comparative example. Experimental results show that the composition provided by the invention has a good inhibition effect on the transformation of bone marrow interstitial cells into fat cells caused by estrogen deficiency.
2) The effect of different compositions on BMD values for bone density in rats is shown in table 4.
TABLE 4 rat bone mineral Density BMD value test results
Note:#P <0.05, vs. sham;*Represents P <0.05, vs. OVX; a. b, c, d, e and f represent multiple comparisons among groups of the middle dose groups of the examples and the comparative examples, and different letters are marked to represent statistical significance, and P is less than 0.05.
compared with the sham operation group, the BMD of the rat in the model control group is obviously reduced (P is less than 0.05), which indicates that the model is successfully established. Compared with a model control group, the rat bone density BMD of the individual dose groups of the high, medium and low dose groups and some comparative examples in the examples is significantly different from that of the model control group (P is less than 0.05), and multiple comparisons among the groups of the medium dose groups in the examples and the comparative examples show that the effect of the example group is significantly better than that of the comparative example group, which indicates that the raw materials used by the composition provided by the invention have a synergistic effect, so that the effect of the composition is integrally improved.
3) The effect of different compositions on rat femoral dry weight, the results are shown in table 5.
TABLE 5 rat femoral shaft weight detection results
Note:#P <0.05, vs. sham;*Represents P <0.05, vs. OVX; a. b, c, d, e, f tablesMultiple comparisons between groups were performed for the medium dose groups of the examples and comparative examples, with different letters indicating statistical significance, P < 0.05.
The dry weight of the model group femur is significantly reduced compared with the sham operation group (P is less than 0.05), indicating that the model is successfully established. Compared with a model control group, the weight average of femoral shafts of the high, medium and low dose groups of each example and the medium dose group of the comparative example 10 is increased and has significant difference (P is less than 0.05) in the positive control group, and the multiple group comparison of the medium dose groups of each example and the comparative example shows that the effect of the example is significantly better than that of the comparative example and has significant difference (P is less than 0.05), which indicates that the composition of the invention has good effect of increasing the dry weight of the femur.
4) Effect of different compositions on morphological changes of bone tissue
(ii) influence of different compositions on bone and mineral content and tissue bone and mineral content parameters, the results obtained are shown in Table 6.
TABLE 6 rat bone mineral content and tissue bone content test results
note:#P <0.05, vs. sham;*Represents P <0.05, vs. OVX; a. b, c, d, e, f and g represent multiple comparisons among groups of the middle dose groups of examples and comparative examples, and are marked with different letters to represent statistical significance, and P is less than 0.05.
After the rats are ovariectomized, compared with a sham operation group, the bone mineral content and the tissue mineral content of the rats in a control group of the model group are remarkably reduced (P is less than 0.05), which indicates that the model is successfully established. Compared with a model control group, the high, medium and low dose groups of each example and some dose groups of some comparative examples can obviously improve the bone mineral content and the tissue mineral content (P <0.05), and multiple comparison results among the groups of the medium dose groups of the examples and the comparative examples show that the composition effect of the examples is obviously better than that of the comparative examples.
② the influence of different compositions on the trabecular bone parameters of the right femur of the rat, the obtained results are shown in Table 7.
TABLE 7 detection results of parameters of trabecular bone of right femur of rat
Note:#P <0.05, vs. sham;*Represents P <0.05, vs. OVX; a. b, c, d, e, f and g represent multiple comparisons among groups of the middle dose groups of examples and comparative examples, and are marked with different letters to represent statistical significance, and P is less than 0.05.
compared with a sham operation group, the number of the rat bone trabeculae in the model group is obviously reduced (P <0.05), the separation degree of the bone trabeculae is obviously increased (P <0.05), and the rat bone trabeculae become sparse after the rat goes to the ovary, so that the model is successfully established. Compared with a model control group, the embodiment can remarkably improve the number of trabeculae (P <0.05) and remarkably reduce the separation degree of the trabeculae (P <0.05), and the effect is far better than that of a comparative example. Namely, the composition provided by the invention can better contribute to the increase of the number of the trabeculae of the rat bone and improve the osteoporosis symptom.
The test results show that the composition provided by the invention has a good effect of increasing the bone density of rats.
Claims (10)
1. A composition for increasing bone density, comprising:
2-3 parts of cistanche deserticola;
25-35 parts of dietary fiber.
2. The composition according to claim 1, wherein the dietary fiber is selected from one or more of inulin, konjac, soy dietary fiber, soy polysaccharide, corn starch, resistant dextrin, cyclodextrin, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, sodium carboxymethyl cellulose and microcrystalline cellulose.
3. The composition according to claim 1, wherein the content of cistanche deserticola is 2.5-3 parts by weight; the content of the dietary fiber is 30 parts by weight.
4. the composition of claim 1, further comprising one or more of fructus Psoraleae, rhizoma Drynariae and herba Epimedii; the content of the fructus psoraleae is 2-3 parts by weight; the content of the rhizoma drynariae is 1-1.5 parts by weight; the content of the epimedium is 2-3 parts by weight.
5. The composition of claim 1, further comprising one or more of eucommia ulmoides, puerariae radix, polygonatum sibiricum, dioscorea opposita, lycium barbarum, notoginseng radix, poria cocos, astragalus membranaceus, and achyranthes bidentata; the content of the eucommia ulmoides is 2-3 parts by weight; the content of the kudzu root is 3.5-5 parts by weight; the content of the sealwort is 3-4.5 parts by weight; the content of the Chinese yam is 5-7.5 parts by weight; the content of the wolfberry fruit is 2-3 parts by weight; the content of the pseudo-ginseng is 1-1.5 parts by weight; the content of the poria cocos is 3.5-5 parts by weight; the content of the astragalus is 3-4.5 parts by weight; the content of the achyranthes bidentata is 2-2.5 parts by weight.
6. the composition of claim 1, further comprising one or more of schisandra chinensis, dodder, prepared rhizome of rehmannia, dogwood, phellodendron, salvia miltiorrhiza, angelica, morinda officinalis and cinnamon; the content of the schisandra chinensis is 0.7-1 part by weight; the content of the semen cuscutae is 2-3 parts by weight; the content of the prepared rhizome of rehmannia is 3-4.5 parts by weight; the content of the dogwood is 2-3 parts by weight; the content of the phellodendron is 1-1.5 parts by weight; the content of the salvia miltiorrhiza is 3.5-5 parts by weight; the content of the angelica is 2-3 parts by weight; the content of the morinda officinalis is 1-1.5 parts by weight; the content of the cinnamon is 0.4-0.5 part by weight.
7. the composition as claimed in claim 1, comprising:
8. the composition as claimed in claim 1, comprising:
9. Use of the composition according to any one of claims 1 to 8 for the preparation of a health product for ameliorating and/or preventing osteoporosis.
10. Use of a composition according to any one of claims 1 to 8 for the preparation of a medicament for the treatment and/or prevention of osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810595497.4A CN110575466A (en) | 2018-06-11 | 2018-06-11 | Composition for increasing bone mineral density and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810595497.4A CN110575466A (en) | 2018-06-11 | 2018-06-11 | Composition for increasing bone mineral density and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110575466A true CN110575466A (en) | 2019-12-17 |
Family
ID=68809887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810595497.4A Pending CN110575466A (en) | 2018-06-11 | 2018-06-11 | Composition for increasing bone mineral density and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110575466A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113648368A (en) * | 2020-05-12 | 2021-11-16 | 辽宁医学诊疗科技研发中心有限公司 | Anti-osteoporosis granules |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462809A (en) * | 2011-12-26 | 2012-05-23 | 厦门中药厂有限公司 | Traditional Chinese medicine composition for treating osteoporosis |
| CN103340341A (en) * | 2013-07-03 | 2013-10-09 | 山西大学 | Functional food with bone strengthening effect and preparation method thereof |
| CN107582864A (en) * | 2017-08-29 | 2018-01-16 | 成都风靡生物科技有限公司 | A kind of Chinese medicine composition for treating osteoporosis and preparation method thereof |
| CN108095114A (en) * | 2017-12-28 | 2018-06-01 | 武汉同济现代医药科技股份有限公司 | A kind of Chinese medicine and health food for increasing bone density and preparation method thereof |
-
2018
- 2018-06-11 CN CN201810595497.4A patent/CN110575466A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462809A (en) * | 2011-12-26 | 2012-05-23 | 厦门中药厂有限公司 | Traditional Chinese medicine composition for treating osteoporosis |
| CN103340341A (en) * | 2013-07-03 | 2013-10-09 | 山西大学 | Functional food with bone strengthening effect and preparation method thereof |
| CN107582864A (en) * | 2017-08-29 | 2018-01-16 | 成都风靡生物科技有限公司 | A kind of Chinese medicine composition for treating osteoporosis and preparation method thereof |
| CN108095114A (en) * | 2017-12-28 | 2018-06-01 | 武汉同济现代医药科技股份有限公司 | A kind of Chinese medicine and health food for increasing bone density and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘小杰: "菊粉与骨健康的研究", 《中国食品添加剂》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113648368A (en) * | 2020-05-12 | 2021-11-16 | 辽宁医学诊疗科技研发中心有限公司 | Anti-osteoporosis granules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102492596B (en) | Body-building and health-care medicinal liquor | |
| CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
| CN101269170B (en) | A kind of medicine for treating climacteric syndrome and preparation method thereof | |
| CN104958646A (en) | Chinese medicinal preparation for relaxing bowels and preparation method thereof | |
| CN100402081C (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN101940621A (en) | Chinese medicinal composition and preparation for relaxing bowel and preparation method thereof | |
| CN105412859A (en) | Chinese medicine composition for preventing and treating postpartum puerperal fever and preparation method thereof | |
| CN110575466A (en) | Composition for increasing bone mineral density and application thereof | |
| CN111388639B (en) | Phenylethanoid glycoside and isoflavone extract for relieving menopausal syndrome and application thereof | |
| CN103520354B (en) | Traditional Chinese medicine for treatment of blood-insufficiency type mammary gland hyperplasia and preparation method thereof | |
| CN114099626A (en) | Multifunctional composition for human body health care and preparation method and application thereof | |
| CN108938747A (en) | It is a kind of increase bone density composition and its application | |
| CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
| CN104083621A (en) | Traditional Chinese medicine preparation for treating hyperlipidemia | |
| CN103784736A (en) | Medicine composition for treating pregnancy toxaemia of equus animals | |
| CN109200162A (en) | A kind of Chinese materia medica preparation that treating Stein-Leventhal syndrome and preparation method | |
| CN101934046A (en) | Semifluid extract of deer foetus and preparation method thereof | |
| CN104940526A (en) | Medicine composition for bone fracture and preparing method of medicine composition | |
| CN107441313B (en) | Traditional Chinese medicine composition, medicine and preparation method for treating decreased ovarian reserve | |
| CN105125980A (en) | Birth promoting and sperm generating particle | |
| CN105726864A (en) | Healthcare wine for treating infertility | |
| CN106109916A (en) | A kind of Fructus Rosae Laevigatae health care oral liquid of slow down aging and preparation method thereof | |
| CN105055823A (en) | Traditional Chinese medicine for treating hashimoto thyroiditis | |
| CN105412673A (en) | Drug for treating Hashimoto disease and preparing method thereof | |
| CN105148164A (en) | Antai Buqi Chinese herbal medicament for livestock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191217 |
|
| RJ01 | Rejection of invention patent application after publication |